Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | AKT2 | P31751 | 2/20 | 0.41 |
| ▸ | BRD4 | O60885 | 2/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | BRD2 | P25440 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.39 |
| ▸ | TDO2 | P48775 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PRNP | P04156 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.38 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3712907 | 0.86 | KDM4E (0.56) | L3MBTL1MAPTMAPK1TDP1KDM4E | |
| SCHEMBL12441013 | 0.82 | IKBKB (0.44) | MAPTMAPK1KDM4ERXFP1ALDH1A1 | |
| SCHEMBL28682614 | 0.79 | L3MBTL1 (0.48) | L3MBTL1MAPTMAPK1TDP1KDM4E | |
| SCHEMBL29184327 | 0.78 | MAPK1 (0.50) | L3MBTL1MAPTMAPK1TDP1KDM4E | |
| SCHEMBL13700991 | 0.75 | LMNA (0.55) | L3MBTL1MAPTMAPK1TDP1KDM4E | |
| SCHEMBL10205902 | 0.74 | L3MBTL1 (0.54) | L3MBTL1MAPTTDP1KDM4EAKT2 | |
| SCHEMBL31504610 | 0.74 | L3MBTL1 (0.54) | L3MBTL1MAPTMAPK1TDP1KDM4E | |
| SCHEMBL3711518 | 0.73 | L3MBTL1 (0.52) | L3MBTL1MAPTKDM4EAKT2BRD4 | |
| SCHEMBL3719157 | 0.71 | MAPK1 (0.44) | L3MBTL1MAPTMAPK1TDP1KDM4E | |
| SCHEMBL28855851 | 0.71 | LMNA (0.52) | TDP1KDM4EKMT2APRNPRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102361872-B | Fused pyrimidines as AKT inhibitors | BAYER SCHERING PHARMA AG | 2014-12-03 | — | — | CN | disclosed |
| US-20130310362-A1 | FUSED PYRIMIDINES | BAYER PHARMA AKTIEGESELLSCHAFT (DE) | 2013-11-21 | — | — | US | disclosed |
| EP-2396331-B1 | FUSED PYRIMIDINES AS AKT INHIBITORS | BAYER IP GMBH (DE) | 2013-10-16 | — | — | EP | disclosed |
| EP-2396331-A1 | FUSED PYRIMIDINES AS AKT INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2011-12-21 | — | — | EP | disclosed |
| WO-2010091824-A1 | FUSED PYRIMIDINES AS AKT INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310362-A1 | FUSED PYRIMIDINES | PIK3CA, MTOR, PIK3CD | L3MBTL1 3795/4885MAPT 475/4885MAPK1 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.